Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA Repair in pulmonary arterial hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 50, Issue 6, 2014, Pages 1118-1128

  Li, Molong ^a,b   Vattulainen, Sanna ^c   Aho, Joonas ^b   Orcholski, Marc ^d   Rojas, Vanessa ^d   Yuan, Ke ^d   Helenius, Mikko ^c   Taimen, Pekka ^e   Myllykangas, Samuel ^c   De Jesus Perez, Vinicio ^d   Koskenvuo, Juha W ^b,f   Alastalo, Tero Pekka ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF TURKU   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Endothelial dysfunction; Metaanalysis; Oxidative stress; Pulmonary hypertension; Vasculopathy

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BRCA1 PROTEIN; DNA; MITOMYCIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; DNA METABOLISM; DNA REPAIR; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG ENDOTHELIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN MICROARRAY; PULMONARY HYPERTENSION; RECEPTOR DOWN REGULATION;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BRCA1 PROTEIN; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHROMATIN; COS CELLS; DNA DAMAGE; DNA REPAIR; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; LUNG; PULMONARY ARTERY; RATS; SIGNAL TRANSDUCTION;

EID: 84901784829     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0349OC     Document Type: Article

References (51)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665.
2. Deng Z, Morse JH, Slager SL, Cuervo N,Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67: 737-744. (Pubitemid 30659603)
3. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA III, Newman J, Williams D, Galiè N, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68:92-102. (Pubitemid 32048364)
4. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-1678. (Pubitemid 34298611)
5. Teichert-Kuliszewska K, Kutryk MJB, Kuliszewski MA, Karoubi G, Courtman DW, Zucco L, Granton J, Stewart DJ. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 2006;98:209-217.
6. de Jesus Perez VA, Alastalo T-P, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 2009;184:83-99.
7. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361: 1533-1544. (Pubitemid 36566349)
8. Masri FA, Xu W, Comhair SAA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B, Erzurum SC. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293:L548-L554. (Pubitemid 47358814)
9. Rai PR, Cool CD, King JAC, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:558-564.
10. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104:1342-1347. (Pubitemid 46184006)
11. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;88:E2-E11.
12. Aldred MAM, Comhair SAS, Varella-Garcia MM, Asosingh KK, Xu WW, Noon GPG, Thistlethwaite PAP, Tuder RMR, Erzurum SCS, Geraci MWM, et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:1153-1160.
13. Alastalo T-P, Li M, Perez V de J, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, et al. Disruption of PPARg/b -catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 2011; 121:3735-3746.
14. Ho Sui SJ, Fulton DL, Arenillas DJ, Kwon AT, Wasserman WW. oPOSSUM: integrated tools for analysis of regulatory motif overrepresentation. Nucleic Acids Res 2007;35:W245-W2452.
15. Fantozzi I, Huang W, Zhang J, Zhang S, Platoshyn O, Remillard CV, Thistlethwaite PA, Yuan JX-J. Divergent effects of BMP-2 on gene expression in pulmonary artery smooth muscle cells from normal subjects and patients with idiopathic pulmonary arterial hypertension. Exp Lung Res 2005;31:783-806. (Pubitemid 41831706)
16. Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, Ahmad F. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;298:H1235-H1248.
17. Olofsson BA, Kelly CM, Kim J, Hornsby SM, Azizkhan-Clifford J. Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia- mutated kinase. Mol Cancer Res 2007;5:1319-1330.
18. Bowen C, Gelmann EP. NKX3.1 activates cellular response to DNA damage. Cancer Res 2010;70:3089-3097.
19. Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010;123: 189-196.
20. Lane KL, Talati M, Austin E, Hemnes AR, Johnson JA, Fessel JP, Blackwell T, Mernaugh RL, Robinson L, Fike C, et al. Oxidative injury is a common consequence of BMPR2 mutations. Pulm Circ 2011;1: 72-83.
21. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001;104:790-795. (Pubitemid 32762677)
22. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan JX-J. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003;285:L740-L754. (Pubitemid 37022876)
23. Bishay K, Ory K, Lebeau J, Levalois C, Olivier MF, Chevillard S. DNA damage-related gene expression as biomarkers to assess cellular response after gamma irradiation of a human lymphoblastoid cell line. Oncogene 2000;19:916-923. (Pubitemid 30153749)
24. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, Dumitrascu R, Seeger W, Knaus P, et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2007; 27:1072-1078. (Pubitemid 46641959)
25. Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, Phillips Iii JA, Gaddipati R, Gladson S, Gu E, et al. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ 2012;3:6.
26. De Siervi A, De Luca P, Byun JS, Di L-J, Fufa T, Haggerty CM, Vazquez E, Moiola C, Longo DL, Gardner K. Transcriptional autoregulation by BRCA1. Cancer Res 2010;70:532-542.
27. Li H, Sekine M, Seng S, Avraham S, Avraham HK. BRCA1 interacts with Smad3 and regulates Smad3-mediated TGF-beta signaling during oxidative stress responses. PLoS ONE 2009;4:e7091.
28. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-182. (Pubitemid 34161138)
29. Deng C-X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006;34: 1416-1426.
30. Troudi W, Uhrhammer N, Ben Romdhane K, Sibille C, Mahfoudh W, Chouchane L, Ben Ayed F, Bignon Y-J, Ben Ammar Elgaaied A. Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer? Eur J Histochem 2007;51:219-226.
31. Henderson BR. The BRCA1 breast cancer suppressor: regulation of transport, dynamics, and function at multiple subcellular locations. Scientifica 2012;2012:1-15.
32. Coene ED, Hollinshead MS, Waeytens AA, Schelfhout VR, Eechaute WP, Shaw MK, Van Oostveldt PM, Vaux DJ. Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria. Mol Biol Cell 2005;16:997-1010. (Pubitemid 40165588)
33. Kulawiec M, Owens KM, Singh KK. Cancer cell mitochondria confer apoptosis resistance and promote metastasis. Cancer Biol Ther 2009; 8:1378-1385.
34. Evans MD, Cooke MS. Factors contributing to the outcome of oxidative damage to nucleic acids. Bioessays 2004;26:533-542. (Pubitemid 38684968)
35. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, Stein GS, Lian JB, Jones SN. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 2006;172:909-921.
36. .Ma G, Li L, Hu Y,Chau JFL, Au BJ, Jia D, Liu H, Yeh J,He L, Hao A, et al. Atypical Atm-p53 genetic interaction in osteogenesis is mediated by Smad1 signaling. J Mol Cell Biol 2012;4:118-120.
37. Kim IY, Lee D-H, Lee DK, Ahn H-J, Kim MM, Kim SJ, Morton RA. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004;23:7651-7659. (Pubitemid 39424923)
38. Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, West J, Moses HL. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci USA 2012; 109:2814-2819.
39. Zhou XP, Woodford-Richens K, Lehtonen R, Kurose K, Aldred M, Hampel H, Launonen V, Virta S, Pilarski R, Salovaara R, et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet 2001;69:704-711. (Pubitemid 32868516)
40. Kodach LL, Wiercinska E, de Miranda NFCC, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJM, Morreau H, et al. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 2008;134:1332-1341.
41. Pangas SA, Li X, Umans L, Zwijsen A, Huylebroeck D, Gutierrez C, Wang D, Martin JF, Jamin SP, Behringer RR, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol 2008;28: 248-257.
42. Cheng K-H, Ponte JF, Thiagalingam S. Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display. Cancer Res 2004;64:1639-1646. (Pubitemid 38428684)
43. Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009;46:331-337.
44. Huang Z, Wang D, Ihida-Stansbury K, Jones PL, Martin JF. Defective pulmonary vascular remodeling in Smad8 mutant mice. Hum Mol Genet 2009;18:2791-2801.
45. Chau JFL, Jia D, Wang Z, Liu Z, Hu Y, Zhang X, Jia H, Lai KP, Leong WF, Au BJ, et al. A crucial role for bone morphogenetic protein-Smad1 signalling in the DNA damage response. Nat Commun 2012;3:836.
46. Hansmann G, de Jesus Perez VA, Alastalo T-P, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008;118: 1846-1857. (Pubitemid 351632387)
47. Bruemmer D, Yin F, Liu J, Berger JP, Sakai T, Blaschke F, Fleck E, Van Herle AJ, Forman BM, Law RE. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferatoractivated receptor gamma in vascular smooth muscle cells. Circ Res 2003;93:e38-e47.
48. Han EJ, Im C-N, Park SH, Moon E-Y, Hong SH. Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARg-independent upregulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells. Int J Radiat Oncol Biol Phys 2013;85:e239-e248.
49. Miyagishi M, Fujii R, Hatta M, Yoshida E, Araya N, Nagafuchi A, Ishihara S, Nakajima T, Fukamizu A. Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/ p300. J Biol Chem 2000;275:35170-35175.
50. Ho T-C, Chen S-L, Yang Y-C, Liao C-L, Cheng H-C, Tsao Y-P. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc Res 2007;76: 213-223. (Pubitemid 350198595)
51. Fisher AB, Chien S, Barakat AI, Nerem RM. Endothelial cellular response to altered shear stress. Am J Physiol Lung Cell Mol Physiol 2001;281: L529-L533.